gretel
31 Dec 2014
Re: Tipped for 2015 in today's Daily Mail The Daily Mail have tweaked their page of tips for 2015 and now include the narrative for AKR's tip as follows - note that the m/cap is only £11m, not the quoted £15m:[link] Lyall - Akers BioscienceIf you look at the share price chart of Akers Bioscience you’d think it hadn’t been a particularly clever year for the diagnostics company. Yet in the past 12 months it has done everything it said it would. The company has developed a rapid test for an allergic reaction to the blood thinner heparin. In the developed Western medical system it offers a cheap and very timely alternative to the current lab tests. In developing economies such as China, where there currently are no lab tests, it will go on to be the gold standard diagnostic. Indeed the group received its first big order (for £640,000) from the People’s Republic. There is the promise of more of these deals next year as Akers continues to sign distribution agreements. Broker finnCap says the firm will break even in 2016; however at the current run rate the golden milestone could come much earlier. It has around £8million of cash in the bank – enough to last three years – and is valued at just £15.5million. The heparin test is the first of a number of potential big sellers rolling off the Akers production line, including rapid diagnostics for lung cancer and cholesterol."
gretel
30 Dec 2014
Tipped for 2015 in today's Daily Mail Excellent news:[link] the online version has somehow omitted the narrative....
gretel
22 Dec 2014
Re: 40% upside on current price Hi TradedOption.AKR is so far off the radar it isn't on it at all!However - Finncap have just initiated coverage. They're a quality house and should encourage interest.And Finncap is still a small - and pretty illiquid - stock.Once there's a little bit of interest I think the price in the US will start to fly - at least back to the $5.50 IPO price, which would equate to around 340p over here.Meanwhile, we have the comfort of knowing that the vast majority of the current £11m m/cap is covered by the $10.8m or so cash pile, with the core business in for almost nothing.
TradedOption
18 Dec 2014
Re: 40% upside on current price Hi Gretel,The coverage may be good, but it is taking a bit to get this moving. The news flow has been positive for a while but the price doesn't seem to want to reflect it.There's an interesting dislocate between the price of the US quoted shares and the UK. US should be around $3.40 rather than $3.05 based on the current exchange rate.
gretel
18 Dec 2014
40% upside on current price Finncap reiterate their 310p target price after today's news (they also note in today's update the $10.2m net cash pile, which is not far off the entire £11m m/cap), against the current 225p share price:[link]
gretel
18 Dec 2014
European distribution agreements Excellent news - AKR now have their first European international distribution agreements:[link] Belgium, the Netherlands, Luxembourg, Switzerland and Lichtenstein are hopefully just the start.Looks like sizeable, respected partners too.The scale of the opportunity dwarfs the £10.7m m/cap since these add to "the already established distribution channels in the US, China, India, Australia and the Middle East".
gretel
15 Dec 2014
Encouraging new interview New Proactive interview - here's a direct link:[link] Good to hear: - the Novotek deal is a "gamechanger" - Novotek sales may be minimum $30m and perhaps even greater than Finncap's $67m - AKR's $10m+ cash pile should remain largely intact until cash break-even - the Chinese market is even greater than the US's $200m-$400m per annumAll this for a company with a mere £10.9m m/cap almost entirely covered by its cash pile!
gretel
15 Dec 2014
Re: Huge contract revenue potential Hi TradedOption - the info comes directly from Finncap's update note after the Novotek contract win which I have in my possession.See also the interview with the CEO which I'm about to post.
TradedOption
12 Dec 2014
Re: Huge contract revenue potential Hi,Where did you get the information about contact value in future years?
gretel
11 Dec 2014
Huge contract revenue potential Finncap retain their Buy and 310p valuation following yesterday's contract news - but in their note they also have this little gem. Not bad for a £11m m/cap company with cash almost equating to the m/cap:"Deal worth minima of US$67.2m. NovoTek is Akers' distribution partner for PIFA Heparin PF4 and PIFA PLUSS PF4 in China. The agreement is for nine years following regulatory approval and contains contractual minima: $1m per annum in years one to three, $4.8m in years four and five, $11.5m in years six and seven, rising to $15.8m in years eight and nine".
gretel
10 Dec 2014
Good coverage in today's Times [link] test with flying colours In a dismal market, Akers Biosciences held firm. This is the £8.5 million New Jersey-based, AIM-quoted specialist in on-the-spot medical tests. Last year, Akers became only the third supplier of portable breathalysers to be awarded the NF Mark, a French kitemark, in a country where every driver on its roads must carry a working, unused, disposable breathalyser. It is also developing a fast test to diagnose lung cancer via breath. Its premium test, Heparin PF4 Rapid Assay, is on sale in the United States, where it helps to determine in minutes whether any patient being treated with the widely used blood-thinner is developing a potentially fatal allergic reaction. About 12 million patients there are given heparin every year and as many as 5 per cent develop an allergy. Yesterday, there were whispers that Akers had received its first $1 million order for the same test from China. Unlike in the US, where there is a slower laboratory test for this allergy, China has no competing test and could become the second-biggest market for the product. Akers shares, 124p two years ago, as high as 690p a little over a year ago, marked time at 215p."
gretel
10 Dec 2014
"Initial" $1m order from China.... Just announced....Wow - remember that AKR's m/cap is only £10.8m and is virtually covered by its cash pile. And this is just an initial order, with no competition whatsoever in the Chinese market and backing from the huge Novotek....[link] Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company"
, a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the receipt of an initial purchase order (the "Order" valued at US$1,000,000 from NovoTek Therapeutics Inc. ("NovoTek" to supply PIFA Heparin PF4/Rapid Assay products in Mainland China ("China".NovoTek, a Beijing‐based pharmaceutical and medical device business development company, holds the exclusive sales and marketing rights for the Company's PIFA Heparin/PF4 Rapid Assay products in China. The Company expects to deliver the Order by December 31, 2014.etc""NovoTek Therapeutics Inc. is a vital part of NovoTek Group, and is in charge of all international business. To date, NovoTek Group has grown to seven subsidiary companies focused on pharmaceutical marketing, medical and IVD products marketing, and contract research services. NovoTek has its own preclinical research facility, clinical trial and regulatory teams, and more than 600 sales representatives (500 for pharmaceuticals and 100 for medical devices) across China. NovoTek has more than 800 employees and more than 10 local branches nationwide. www.novotekchina.com "
gretel
19 Nov 2014
New analyst report - large upside New Redchip research report just out - note the $10.8m cash compared to the £10.65m m/cap:[link] price of $11.40. We are applying a 5.0x P/S multiple to our projected FY15 revenue per share of $2.25. Our target price offers significant upside from the current price of $3.13. We believe the current entry point is very attractive, especially considering that AKER is trading just below book value (0.99x), has no debt, is generating revenue both domestically and internationally and has many pending product launches on the horizon."
